We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
AmoyDx® is a research and development-based diagnostics company with over 1000 employees that focuses on molecular diagnostics for oncological precision medicine. The primarily CE/IVD labeled qPCR and NGS products have proven to be of excellent quality and reliability, as confirmed by numerous successful external proficiency tests conducted by our customers. Furthermore, our product and laboratory team are happy to offer advice and active support during the introduction and establishment of the products.
If you are interested, please do not hesitate to contact your local contact at ZytoMax Schweiz GmbH, via e-mail at info@zytomax.ch or phone at +41 79 965 68 67.
Even faster NGS data analysis with the new ANDAS-T2 from AmoyDx®
For the analysis of sequencing data generated with AmoyDx® NGS kits, Zytomed Systems offers the AmoyDx® NGS Data Analysis System (ANDAS) from our partner company AmoyDx®.
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)